October 28, 2015
TraceLink Inc., the world’s largest track and trace network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced financial results for the third quarter 2015. Growth highlights for the quarter include:
“We continue to experience widespread adoption of our solutions. As pharmaceutical companies, CMOs, wholesale distributors, and dispensers evaluate their options for compliance, most recognize that the Life Sciences Cloud offers the widest range of integrated, out-of-the-box drug traceability solutions that require the least amount of cost, implementation time, and risk,” said Shabbir Dahod, president and CEO of TraceLink. “While other companies provide point solutions for compliance, TraceLink is the only company transforming the global pharmaceutical supply chain into an end-to-end digital network. With nearly 200,000 pharmaceutical suppliers exchanging compliance data on the Life Sciences Cloud, we’re seeing a dramatic increase in the number of companies seeking our solutions once they learn that 90 percent of their suppliers, or greater, are already on the TraceLink network.”
Additional growth highlights for the third quarter include:
To learn more about meeting global pharmaceutical compliance deadlines and how to build a flexible serialization, track and trace, and reporting platform for the US, the EU, China, Brazil, Germany, South Korea, India, Turkey, Argentina and other countries, please visit www.tracelink.com.